Alto Pharmacy Exit Candidate
π¦ Potential exit path:
SPAC, IPO, M&A

Select partners: New York City Health Department.
Funding π°
Total
π¦ $612.4M
Select investors SoftBank Vision Fund, Greenoaks Capital, Zola Global, Olive Tree Capital, Jackson Square Ventures, Nimble Ventures, Esas Ventures
Key people π§βπ€βπ§
- Kevin Burns - CEO
- Mattieu Gamache-Asselin - Co-founder
- Jamie Karraker - Co-founder & CTO
- Francis Nzeuton - CFO
- Michael Krueger - CMO
- Ajay Khatri - Chief Strategy and Business Officer
- Neil Frye - Chief People Officer
- Jared Fix - Chief Commercial Officer
Highlights β
- Alto's service is already making a big impact, resulting in 40% better adherence than the industry average while bringing prescription savings to patients (41%+).
- As of January 2020, Alto is available in 12 markets across the United States, with its revenues growing to over $700 million annual run rate - up more than 100% in the last 12 months. π
- Alto has consistently earned a Net Promoter Score of 86, which is on par with top brands like Tesla and Apple - compared to negative five for the leading retail chain pharmacy. π
- "Alto's growth is a testament to their focus on improving the patient experience. By reimagining the core pharmacy software, we believe Alto has improved the quality of care and health outcomes for over 50,000 patients in California." - Neil Shah at Greenoaks Capital π
- In August 2021, the company got an experienced CEO - Kevin Burns, who was previously CEO at JUUL Labs and before that, President and COO at Chobani. π
Last update: February 2, 2022
Disclaimer: We can not guarantee that the information on this page is 100% correct. more